Resilience Biotechnologies Inc. (RBI), a centre for excellence for contract manufacturing of biologics and vaccines, is planning to undertake an internal fill line optimization project (Phase 1), as well as a major fill-finish expansion (Phase 2). Phase 1 consisted of creating additional clean room infrastructure to optimize existing scale fill-finish operations. Phase 2 will consist of creating two additional isolator-based high speed commercial fill-finish and automated inspection lines to produce drug product for vaccines, mAb, and related therapeutic proteins.

Scope of services include owner representation during the design phase, design and costing peer review, constructability assessments, construction plan, scheduling, and construction services.